Related Experiment Video

Updated: Oct 18, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.3K

Osimertinib in NSCLC: Real-World Data From New Zealand

Yeojeong Jane So1, Anne Fraser1, Gareth Rivalland1

  • 1Auckland City Hospital, Grafton, Auckland, New Zealand.

JTO Clinical and Research Reports
|September 30, 2021
PubMed
Abstract

Insights

Osimertinib effectively treats EGFR T790M-mutated NSCLC in New Zealand patients who progressed on prior therapies. This EGFR TKI demonstrated a 70% overall response rate and good tolerability in the study population.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • EGFR tyrosine kinase inhibitors (TKIs) are superior to chemotherapy for EGFR-mutant non-small cell lung cancer (NSCLC).
  • Acquired resistance, often due to EGFR T790M mutation, is a common cause of disease progression on EGFR TKI therapy.
  • Osimertinib, a third-generation EGFR TKI, offers improved outcomes for EGFR T790M-positive NSCLC compared to chemotherapy.

Purpose of the Study:

  • To retrospectively review the clinical outcomes of patients with EGFR T790M-mutated NSCLC treated with osimertinib in New Zealand.
  • To evaluate the efficacy and tolerability of osimertinib in a compassionate access program setting.

Main Methods:

  • Retrospective review of clinical data from 37 patients with EGFR T790M-mutated NSCLC who received osimertinib.
  • EGFR T790M mutation status confirmed via biopsy or circulating tumor DNA (ctDNA).
  • Survival outcomes calculated from the initiation of osimertinib treatment.

Main Results:

  • An overall response rate of 70% was observed (26/37 patients).
  • Median progression-free survival (PFS) was 14.6 months, with 62% PFS at 12 months.
  • Osimertinib was generally well-tolerated, with common adverse events including grade 1 gastrointestinal and skin toxicity.

Conclusions:

  • Osimertinib is an effective treatment option for New Zealand patients with EGFR T790M-mutated NSCLC who have progressed on prior therapies.
  • The study supports the use of osimertinib in this patient population, demonstrating favorable efficacy and tolerability.
Keywords:
Epidermal growth factor receptorNew ZealandNon–small cell lung cancerOsimertinibT790M mutationTyrosine kinase inhibitor

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.1K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
248
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.9K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.8K